CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir +12 more
wiley +1 more source
Blockchain-enhanced incentive-compatible mechanisms for multi-agent reinforcement learning systems. [PDF]
Tian K.
europepmc +1 more source
Flexibility Incentive Market Mechanism for Combined Frequency Regulation and Electricity Markets for the Power System with Distributed Energy Resources Aggregators via Modified Leiden Algorithm [PDF]
Xiao Hu +5 more
openalex +1 more source
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
Implementation of Web-Based Respondent-Driven Sampling to Recruit Users of Electronic Nicotine Delivery Systems in Brazil: Cross-Sectional Survey. [PDF]
Bertoni N, Szklo AS, Bastos FI.
europepmc +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Beyond fresh: implications of produce prescription policy for food systems transformation. [PDF]
Byker Shanks C +2 more
europepmc +1 more source
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Response to Letter to the Editor: Optimizing Pulmonary Health and Quality of Life in Breast Cancer Survivors: A Randomized Controlled Trial Combining Incentive Spirometry and Aerobic Exercise. [PDF]
Sari DM +6 more
europepmc +1 more source

